Praxis (PRAX) Files Form 4: Director Receives New Equity Incentive

Rhea-AI Filing Summary

Praxis Precision Medicines, Inc. (PRAX) — Form 4 insider filing

Director Jill DeSimone received a new option grant on 26 June 2025. The grant covers 10,520 shares of common stock at an exercise price of $44.04 and expires on 26 June 2035. Vesting is scheduled in twelve equal monthly installments over one year beginning on the grant date, aligning compensation with near-term company performance. After this transaction Ms. DeSimone holds 10,520 derivative securities directly. No common-stock transactions, sales, or additional option exercises were reported.

The filing represents a routine equity incentive for a non-employee director and does not change PRAX’s share count in a material way. The transaction code "A" confirms an acquisition of options rather than an open-market purchase, so immediate cash outlay or insider buy-signal implications are minimal.

Insights

Corporate Governance Expert

TL;DR: Standard director option grant; aligns incentives, immaterial to float.

This Form 4 reflects a customary annual equity award for an independent director. The one-year monthly vesting schedule incentivises short-term engagement without over-leveraging equity compensation. With only 10.5 k options granted, the potential dilution is de minimis relative to PRAX’s ~47 m shares outstanding. No red flags appear regarding grant size or pricing; the strike at $44.04 mirrors recent market levels, preserving accounting neutrality under ASC 718. Impact on governance quality is modestly positive but financially negligible.

Securities Analyst

TL;DR: Neutral—routine compensation, no buy/sell signal.

The filing does not indicate insider confidence through open-market buying; it is a scheduled option grant coded "A". Because the award has a 10-year term and vests monthly, the director is not likely to exercise imminently, so no liquidity event is expected. Investors should view this as administrative rather than indicative of near-term fundamentals. Overall share-based compensation expense will rise slightly, but at this scale EPS impact rounds to zero.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeSimone Jill

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$44.04	06/26/2025		A		10,520		(1)	06/26/2035	Common Stock	10,520	$0	10,520	D

Explanation of Responses:

1. The shares subject to this option shall vest in twelve (12) equal monthly installments over one (1) year commencing on June 26, 2025.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Praxis Precision Medicines (PRAX) report on this Form 4?

An option grant of 10,520 shares to director Jill DeSimone at an exercise price of $44.04, dated 26 Jun 2025.

Does the filing show any insider buying or selling of PRAX common stock?

No. It discloses only an option acquisition; there were no direct stock purchases or sales.

When do the options granted to Jill DeSimone vest and expire?

They vest in 12 equal monthly installments over one year starting 26 Jun 2025 and expire on 26 Jun 2035.

How many derivative securities does the director own after the transaction?

Ms. DeSimone beneficially owns 10,520 stock options following the reported grant.

Is the transaction likely to materially dilute existing PRAX shareholders?

Dilution is immaterial; 10,520 options represent far less than 1% of outstanding shares.